The Experts below are selected from a list of 3 Experts worldwide ranked by ideXlab platform

Michael A Mckusick - One of the best experts on this subject based on the ideXlab platform.

  • preliminary study of the use of drug eluting stents in atherosclerotic renal Artery stenoses 4 mm in diameter or Smaller
    Journal of Vascular and Interventional Radiology, 2008
    Co-Authors: Sanjay Misra, Mallik R Thatipelli, Patrick W Howe, Christopher H Hunt, Verghese Mathew, Gregory W Barsness, Axel Pflueger, Stephen C Textor, Haraldur Bjarnason, Michael A Mckusick
    Abstract:

    Purpose To describe restenosis and clinical outcomes with drug-eluting stents (DESs) and compare them to those of bare metal stents (BMSs) in the treatment of symptomatic atherosclerotic renal Artery stenosis (RAS) in the same patients. Methods and Materials A retrospective study was performed of all patients with RAS treated with a DES (Taxus Express 2 or Cypher). DESs were used for RASs with luminal vessel diameters of 4 mm or Smaller and BMSs were used for those larger than 4 mm. Results Sixteen patients (eight women; mean age, 72 years ± 8) underwent treatment of 27 RASs for worsening renal function ( n = 10) and uncontrolled hypertension ( n = 6). Eighteen RASs were treated with 23 DESs (Cypher, n = 12; Taxus, n = 11) and nine were treated with BMSs. The average follow-up was 22 months ± 10. After the procedure, the mean systolic blood pressure decreased significantly ( P P = NS). The average diameters of RASs were 3.4 mm ± 0.6 in the DES group and 5.3 mm ± 0.6 in the BMS group ( P Conclusions DESs were used to treat RASs with good technical results and low restenosis rates compared with BMSs despite the Smaller Artery diameters in the DES group.

Sanjay Misra - One of the best experts on this subject based on the ideXlab platform.

  • preliminary study of the use of drug eluting stents in atherosclerotic renal Artery stenoses 4 mm in diameter or Smaller
    Journal of Vascular and Interventional Radiology, 2008
    Co-Authors: Sanjay Misra, Mallik R Thatipelli, Patrick W Howe, Christopher H Hunt, Verghese Mathew, Gregory W Barsness, Axel Pflueger, Stephen C Textor, Haraldur Bjarnason, Michael A Mckusick
    Abstract:

    Purpose To describe restenosis and clinical outcomes with drug-eluting stents (DESs) and compare them to those of bare metal stents (BMSs) in the treatment of symptomatic atherosclerotic renal Artery stenosis (RAS) in the same patients. Methods and Materials A retrospective study was performed of all patients with RAS treated with a DES (Taxus Express 2 or Cypher). DESs were used for RASs with luminal vessel diameters of 4 mm or Smaller and BMSs were used for those larger than 4 mm. Results Sixteen patients (eight women; mean age, 72 years ± 8) underwent treatment of 27 RASs for worsening renal function ( n = 10) and uncontrolled hypertension ( n = 6). Eighteen RASs were treated with 23 DESs (Cypher, n = 12; Taxus, n = 11) and nine were treated with BMSs. The average follow-up was 22 months ± 10. After the procedure, the mean systolic blood pressure decreased significantly ( P P = NS). The average diameters of RASs were 3.4 mm ± 0.6 in the DES group and 5.3 mm ± 0.6 in the BMS group ( P Conclusions DESs were used to treat RASs with good technical results and low restenosis rates compared with BMSs despite the Smaller Artery diameters in the DES group.

Mallik R Thatipelli - One of the best experts on this subject based on the ideXlab platform.

  • preliminary study of the use of drug eluting stents in atherosclerotic renal Artery stenoses 4 mm in diameter or Smaller
    Journal of Vascular and Interventional Radiology, 2008
    Co-Authors: Sanjay Misra, Mallik R Thatipelli, Patrick W Howe, Christopher H Hunt, Verghese Mathew, Gregory W Barsness, Axel Pflueger, Stephen C Textor, Haraldur Bjarnason, Michael A Mckusick
    Abstract:

    Purpose To describe restenosis and clinical outcomes with drug-eluting stents (DESs) and compare them to those of bare metal stents (BMSs) in the treatment of symptomatic atherosclerotic renal Artery stenosis (RAS) in the same patients. Methods and Materials A retrospective study was performed of all patients with RAS treated with a DES (Taxus Express 2 or Cypher). DESs were used for RASs with luminal vessel diameters of 4 mm or Smaller and BMSs were used for those larger than 4 mm. Results Sixteen patients (eight women; mean age, 72 years ± 8) underwent treatment of 27 RASs for worsening renal function ( n = 10) and uncontrolled hypertension ( n = 6). Eighteen RASs were treated with 23 DESs (Cypher, n = 12; Taxus, n = 11) and nine were treated with BMSs. The average follow-up was 22 months ± 10. After the procedure, the mean systolic blood pressure decreased significantly ( P P = NS). The average diameters of RASs were 3.4 mm ± 0.6 in the DES group and 5.3 mm ± 0.6 in the BMS group ( P Conclusions DESs were used to treat RASs with good technical results and low restenosis rates compared with BMSs despite the Smaller Artery diameters in the DES group.

Patrick W Howe - One of the best experts on this subject based on the ideXlab platform.

  • preliminary study of the use of drug eluting stents in atherosclerotic renal Artery stenoses 4 mm in diameter or Smaller
    Journal of Vascular and Interventional Radiology, 2008
    Co-Authors: Sanjay Misra, Mallik R Thatipelli, Patrick W Howe, Christopher H Hunt, Verghese Mathew, Gregory W Barsness, Axel Pflueger, Stephen C Textor, Haraldur Bjarnason, Michael A Mckusick
    Abstract:

    Purpose To describe restenosis and clinical outcomes with drug-eluting stents (DESs) and compare them to those of bare metal stents (BMSs) in the treatment of symptomatic atherosclerotic renal Artery stenosis (RAS) in the same patients. Methods and Materials A retrospective study was performed of all patients with RAS treated with a DES (Taxus Express 2 or Cypher). DESs were used for RASs with luminal vessel diameters of 4 mm or Smaller and BMSs were used for those larger than 4 mm. Results Sixteen patients (eight women; mean age, 72 years ± 8) underwent treatment of 27 RASs for worsening renal function ( n = 10) and uncontrolled hypertension ( n = 6). Eighteen RASs were treated with 23 DESs (Cypher, n = 12; Taxus, n = 11) and nine were treated with BMSs. The average follow-up was 22 months ± 10. After the procedure, the mean systolic blood pressure decreased significantly ( P P = NS). The average diameters of RASs were 3.4 mm ± 0.6 in the DES group and 5.3 mm ± 0.6 in the BMS group ( P Conclusions DESs were used to treat RASs with good technical results and low restenosis rates compared with BMSs despite the Smaller Artery diameters in the DES group.

Christopher H Hunt - One of the best experts on this subject based on the ideXlab platform.

  • preliminary study of the use of drug eluting stents in atherosclerotic renal Artery stenoses 4 mm in diameter or Smaller
    Journal of Vascular and Interventional Radiology, 2008
    Co-Authors: Sanjay Misra, Mallik R Thatipelli, Patrick W Howe, Christopher H Hunt, Verghese Mathew, Gregory W Barsness, Axel Pflueger, Stephen C Textor, Haraldur Bjarnason, Michael A Mckusick
    Abstract:

    Purpose To describe restenosis and clinical outcomes with drug-eluting stents (DESs) and compare them to those of bare metal stents (BMSs) in the treatment of symptomatic atherosclerotic renal Artery stenosis (RAS) in the same patients. Methods and Materials A retrospective study was performed of all patients with RAS treated with a DES (Taxus Express 2 or Cypher). DESs were used for RASs with luminal vessel diameters of 4 mm or Smaller and BMSs were used for those larger than 4 mm. Results Sixteen patients (eight women; mean age, 72 years ± 8) underwent treatment of 27 RASs for worsening renal function ( n = 10) and uncontrolled hypertension ( n = 6). Eighteen RASs were treated with 23 DESs (Cypher, n = 12; Taxus, n = 11) and nine were treated with BMSs. The average follow-up was 22 months ± 10. After the procedure, the mean systolic blood pressure decreased significantly ( P P = NS). The average diameters of RASs were 3.4 mm ± 0.6 in the DES group and 5.3 mm ± 0.6 in the BMS group ( P Conclusions DESs were used to treat RASs with good technical results and low restenosis rates compared with BMSs despite the Smaller Artery diameters in the DES group.